Fig. 4.

(a) CYP2J peptide was immunogenic in naive C3H/HeN mice. Male C3H/HeN mice received subcutaneous injections of CYP2J peptide (20 µg/mouse) with adjuvant on days 1 and 7. Splenocytes were collected on day 14 and cultured for 72 h with or without CYP peptide (20 µg/ml) or control ovalbumin (OVA) peptide (20 µg/ml). Supernatants were examined for interferon (IFN)-γ with enzyme-linked immunosorbent assay. (b) Immunization with CYP2J peptide suppressed the growth of implanted MIH-2 cells in vivo. Male C3H/HeN mice received subcutaneous injections of CYP2J peptide (20 µg/mouse) or OVA peptide (20 µg/mouse) with adjuvant on days 1 and 7. On day 14, the immunized mice were implanted subcutaneously with MIH-2 cells (10⁶/mouse) or murine bladder tumour (MBT) cells (10⁶/mouse), and the tumour size (long diameter × short diameter) was measured 4 weeks after the tumour cell implantation. CYP2J was detectable in MIH-2 cells but not in MBT cells by immunoblot analysis.